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Abstract It has been demonstrated that protein expression of 
p16, the inhibitor of cyclin-dependent kinase 4 and 6, increases 
4 fold at the GIIS transition when serum-arrested cells are restim- 
ulated to logarithmic growth. We examined the cell cycle regula- 
tion of this cyclin-dependent kinase inhibitor in cells separated 
according to their cell cycle phases by centrifugal elutriation. 
Neither p16 mRNA nor its protein expression are regulated dur- 
ing the cell cycle of normal phytohemagglutinin-stimulated lym- 
phocytes, retinoblastoma protein-negative cells, papilloma virus- 
transformed cells, and acute promyelocytic leukemia cells, p16 
mRNA is constitutively expressed in cells in which we detected 
the normal E2F-dependent S-phase specific expression of thymid- 
ine kinase mRNA. We further observed a Gl-phase specific ex- 
pression of cyclin D1 mRNA in the same cells separated by 
centrifugal elutriation. 
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1. Introduction 
p16 was originally described as a protein associated with 
cyclin-dependent kinase 4 (CDK4) in simian virus 40-trans- 
formed fibroblasts [1]. Human p16 cDNA was isolated using 
a yeast two-hybrid protein interaction screen. The cDNA en- 
codes 148 amino acids, respectively a protein of 15.845 molec- 
ular weight comprising four ankyrin repeats. This protein has 
been shown to inhibit the activities of CDK4 and CDK6 in 
vitro [2]. The gene encoding p16 (known as p16 INK4, MTS1, 
CDK4I and CDKN2) is located at chromosome 9p21 and was 
found to be homozygously deleted or mutated in different 
tumor cell lines [3,4]. Since then, functional loss ofpl 6 has been 
reported in a wide variety of primary tumors and tumor derived 
cell lines (reviewed in [5]). The function of p16 as a tumor 
suppressor gene was determined by investigating its ability to 
arrest cell cycle progression. It has been reported that p16 acts 
as a potent inhibitor of progression through the Gl-phase 
whereas tumor-associated mutants of p16 do not. This ability 
of wild type p16 is lost in retinoblastoma protein (pRb)-nega- 
tive cells [6-11]. 
Although the role of p16 in regulating cell proliferation and 
in induction of tumorigenesis has intensively been investigated, 
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little is known about the regulation of p16 expression. It has 
been shown that pl 6 expression is low in logarithmically grow- 
ing primary cells of different origin, whereas everal solid tumor 
cells highly express p16 protein. Interestingly, intracellular p l 6 
protein expression was inducible by transfection with tumor 
antigens of specific DNA-tumor viruses, such as papilloma 
virus, adenovirus, and simian virus 40 [12,13]. Restimulation 
experiments after serum deprivation demonstrated that p16 
protein expression increases about 4-fold during the transition 
from Go to S-phase [12]. Considering these data one could 
speculate that p16 expression is S-phase-regulated viathe tran- 
scription factor E2F. This transcription factor is activated by 
release from pRb prior to the onset of replication. In normal 
cells this release is caused by the phosphorylation f pRb by 
the Gl-cyclin-dependent kinases, CDK2, CDK4, and CDK6. 
In addition, it is known that polyoma virus large T, the large 
T antigen of simian virus 40, the E1A-protein of adenovirus, 
and the E7 protein of papilloma virus share the capacity to bind 
pRb and thereby to activate E2F (reviewed in [14]). Accord- 
ingly, the observation that p16 is overexpressed in DNA tumor 
virus-transformed cells and in pRb-negative cells and the fact 
that p16 protein is regulated uring growth indicate the puta- 
tive role of E2F in the regulation of p16 expression (reviewed 
in [15,16]). The nucleotide upstream sequence, which has been 
shown to promote p16 mRNA expression, has been screened 
for an E2F consensus binding site. Although no apparent E2F 
site was found so far, the question whether p16 contains a 
binding site for this factor is still under investigation. Cotrans- 
fection of a plasmid containing the p16 promoter cloned up- 
stream of a promoterless luciferase gene, and of expressable 
pRb demonstrated that pRb represses mRNA expression 
driven by the p16 promoter [17]. 
From these data a model has been suggested to explain the 
timing of both, the expression and the function of p16 during 
the ongoing cell cycle [12,15 17]. Expression of D-type cyclins 
is high in early G1. These cyclins activate CDK4 and CDK6 
to phosphorylate pRb. Phosphorylation f pRb leads to activa- 
tion of a transcription factor, which promotes the expression 
of p16. Thereupon, p16 inhibits the activity of CDK4 and 
CDK6 by displacing D-type cyclins, which are thereafter (in 
late G1) degraded. In accord, one would expect o see a sharp 
induction of p16 expression in G1 of the ongoing eukaryotic 
cell cycle. To answer this question we investigated p16 expres- 
sion after centrifugal elutriation of normal phytohemag- 
glutinin-stimulated human lymphocytes. We compared this 
normal p16 cell cycle regulation with its regulation in cycling 
pRb-negative c lls and DNA tumor virus-transformed cells. As 
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a control of a transformed cell line with no obvious changes in 
the pRb-involving pathway, we also analysed pl6 cell cycle 
regulation in acute promyelocytic leukemia cells. 
2. Materials and methods 
2.1. Human cells 
HeLa cervix carcinoma cells (papilloma virus-transformed; Ameri- 
can Type Culture Collection CCL2), Y79 retinoblastoma cells (retino- 
blastoma protein-negative; ATCC HTB18), and an acute promyelo- 
cytic leukemia cell line (in this report indicated as APL) were grown in 
RPMI 1640 medium supplemented with 10% calf serum and antibiotics 
(30 mg/liter penicillin, 50 mg/liter streptomycin sulfate). Normal human 
lymphocytes (indicated as PHA-lymph) were isolated from heparinised 
blood of a normal male subject using the Ficoll-Hypaque gradient 
method. These cells were stimulated with 5 ,ug phytohemagglutinin per
ml RPMI medium, composed as described above, for about two cell 
doubling times. Lymphocytes were analysed after reaching logarithmic 
growth. All cultures were maintained at 37°C and 5% CO2, and rou- 
tinely screened for the absence of mycoplasma. 
2.2. Centrifugal elutriation 
Separation of cell cycle phases by centrifugal elutriation was per- 
formed as described [18]. The elutriation system consisted of a Beckman 
J2-21 M centrifuge and a JE-6B rotor eqipped with the standard sepa- 
ration chamber. The rotor was kept at a speed of 2000 rpm, temperature 
was 20°C, and medium flow was controlled with a Cole-Panner Mas- 
terflex pump. Elutriation medium was phosphate buffered saline con- 
taining 0.9 mmol/l CaC12, 0.5 mmol/l MgC12, and 2% calf serum. Con- 
secutive fractions of 150-300 ml were collected at increasing flow rates. 
Cytofluorometric analyses of cell cycle distributions were performed on 
fixed cells using a PAS-I1 flow cytometer (Partec). DNA was stained 
with 6 pmol/1 4,6-diamidino-2-phenylindol-dihydrochloride (DAPI).
2.3. Western blot analysis 
Protein extracts were prepared as described [19]. After washing with 
phosphate-buffered saline cell lysis was performed using a buffer con- 
sisting of 10 mM Tris-HCl (pH 7.5), 250 mM sucrose, 160 mM KC1, 
1.5 mM MgC12, 3 mM fl-mercaptoethanol, 50 mM e-amino-n-capronic 
acid, and 0.8 mg/ml digitonin. Extracts have been stored at -70°C and 
protein concentration was determined using the Bio-Rad protein assay 
reagent with bovine serum albumin as a standard. 
Protein was denatured and reduced in a loading buffer containing 
200 mM dithiotreithol and 4% SDS for 5 min at 95°C. 50-200 pg 
protein per lane were run on a 12.5% SDS-PAA gel and transferred to 
nitrocellulose by electroblotting. Blots were stained with Ponceau-S to 
confirm the loaded amount of protein. After blocking overnight at 4 ° C, 
immunodetection was performed using anti-pl6 antibody (PharMin- 
gen, Cat.No. 15126E) at a dilution of 1:1000 and anti-pRb antibody 
(PharMingen, Cat.No. 14001A) at a dilution of 1:2000. Signals were 
developed using enhanced chemiluminescence (Amersham). Ratio of 
protein expression was determined by scanning the respective signal- 
densities. These values were set relative to the amount of loaded pro- 
tein, 
2.4. Northern blot analysis 
mRNA expression was analysed as described previously [20]. 15 pg 
RNA, prepared by the guanidine isothiocyanate method, were dena- 
tured in 1 M deionized glyoxal, 4.8% dimethyl sulfoxide and 10 mM 
sodium phosphate (pH 6.8) for 1 h at 50°C. After electrophoresis in a 
1% agarose gel, RNA was transferred to nylon membranes in 20 × SSC. 
After UV fixation, filters were hybridized in 1% BSA, 7% SDS, 0.5 M 
sodium phosphate (pH 6.8) and 1 mM EDTA for at least 10 h at 65°C. 
After washing for 20 min in 0.5% BSA, 5% SDS, 40 mM sodium 
phosphate (pH 6.8), 1 mM EDTA, and for 40 min in 1% SDS, 40 mM 
sodium phosphate (pH 6.8), 1 mM EDTA at 65°C, filters were exposed. 
The probes used for hybridization were full length uman p 16/MTS 1 
cDNA [2], full length human thymidine kinase cDNA and cyclin D1 
cDNA, and a 1300 bp cDNA fragment of the glyceraldehyde-3-phos- 
phate dehydrogenase (GAPDH) gene. Filters were stripped between 
hybridizations by incubation in 0.1 x SSC, 0.1% SDS for 25 min at 
95°C. Autoradiographs were densitometrically scanned and quanti- 
rated. 
3. Results 
3.1. Separation of cells in different phases of the cell cycle by 
centrifugal elutriation 
Regulation of gene expression which occurs during the stim- 
ulation of arrested cells (Go) to logarithmical growth is not 
really comparable to gene regulation throughout he ongoing 
cell cycle. Stimulation experiments mainly provide insights into 
the first round of cell cycle, which occurs after cells have been 
arrested by withdrawal of growth factors. Studying the ongoing 
cell cycle means to investigate logarithmically growing cells at 
specific moments when they pass GI-,  S-, G2-, and/or M-phase. 
Counterflow centrifugal elutriation is the best methodical ap- 
proach so far to analyse a regulation occurring during ongoing 
cell cycling. By this method cells are separated on the basis of 
size, and to a lesser extent by density, under very moderate 
conditions. This makes centrifugal elutriation ideal for isolating 
populations of cells in specific phases of the cell cycle with 
minimal perturbation of metabolic function. We separated nor- 
mal phytohemagglutinin-stimulated human lymphocytes 
(PHA-lymph) and three different permanent human cell lines 
(Y79, HeLa, APL) according to their phases of the cell cycle 
by centrifugal elutriation. In the presented experiments, fewer 
and larger fractions were drawn in order to ensure a sufficient 
number of cells per fraction for the analyses of mRNA and/or 
protein expression. About half a million cells per separated 
fraction were stained with 4,6-diamidino-2-phenylindol-dihy- 
drochlorid (DAPI) and cytofluorometrically analysed for DNA 
distribution. As indicated by the flowcytometric data presented 
in Figs. 1, 2 and 3, the separation quality of all performed 
elutriations was comparable. The first fraction contained con- 
stantly more than 80% G1 cells (mean 82%). The best S-phase 
fractions derived from each of the four cell lines also had 
comparable amounts of cells of different cell cycle positions. 
The average distribution of the obtained S-phase fractions was 
15% G1, 71% S, and 14% G2/M. The amount of G2 cells (also 
including mitotic cells) in the end fractions varied from 69% 
(PHA-lymph, Fig. 3) to 84% (HeLa, Fig. 3) (mean of all elutri- 
ations 78%). In general, the separation data were very compa- 
rable to earlier obtained results with the same or similar cells 
[18]. Since the quality of separation was that comparable, we 
concluded that any differences possibly occuring during the cell 
cycle regulation between the studied cell lines would not be 
caused by experimental variations. 
Table 1 
Properties of logarithmically growing human cells 
PHA-lymph Y79 HeLa APL 
(%) (%) (%) (%) 
pRb a 100 0 82 91 
pl6 4 3 100 6 
G1 b 61 44 46 44 
S 25 37 34 41 
G2/M 14 19 20 15 
aRetinoblastoma protein (pRb) and pl6 protein expression were deter- 
mined by Western blot analyses. The blots were densitometrically quan- 
titated and the highest value was set 100%. 
bDNA distributions were determined by Flow Activated Cell Analyses. 
The values are means of three independent determinations. PHA- 
lymph, phytohemagglutinin-stimulated normal lymphocytes; Y79, 
pRb-negative cells; HeLa, papilloma virus-transformed cervic carci- 
noma cells; APL, acute promyelocytic leukemia cells. 
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Fig. 1. Regulation of p16 protein expression throughout the ongoing 
cell cycle. Logarithmically growing phytohemagglutinin-stimulated 
lymphocytes (PHA-lymph) and Y79 cells were separated into fractions 
of different cell cycle phases by centrifugal elutriation. The fractions 
were cytofluorometrically nalysed for DNA distribution (upper panel) 
and for p 16 protein expression by Western blot analysis (middle panel). 
The Western blot signals were densitometrically quantified and related 
to each other by setting the highest value to 100% (lower panel). 
3.2. p16 protein expression throughout the ongoing cell cycle 
It has been observed that p16 protein expression is elevated 
in pRb-negative cells and in DNA tumor virus-transformed 
cells [6,12,13,17]. We compared the levels of protein expression 
ofpRb and p16 in four different human cell lines. Western blot 
analyses using an anti-pRb antibody as well as an anti-pl6 
antibody revealed that the papilloma virus-transformed human 
cell line HeLa expressed 25-fold higher levels of p16 than nor- 
mal phytohemagglutinin-stimulated ymphocytes (Table 1). In 
addition, p16 protein expression was about 16-fold higher in 
logarithmically growing HeLa cells than in cycling acute pro- 
myelocytic leukemia cells. In contrast to data described so far, 
the pRb-negative cell line Y79 did express p16 protein at very 
low levels, comparable to normal lymphocytes. Since it has 
been demonstrated that protein expression of this CDK-inhib- 
itor is growth-regulated [12], one could speculate that its ex- 
pression is also S-phase-regulated during the ongoing cell cycle. 
This correlation stands true for some growth regulated genes 
(e.g. thymidine kinase), but certainly not for all (e.g. c-mye). 
Accordingly, we correlated the amount of S-phase cells to the 
pl 6 protein expression in logarithmically growing cells (Table 
1 ). Normal cycling lymphocytes contained about 17% more G 1 
cells and about 14% less S-phase cells than the pRb-negative 
Y79 cells and the acute promyelocytic leukemia cells (APL). 
Nevertheless, the amount of pl 6 protein expression was almost 
identical in all three lines. Furthermore, although logarithmi- 
cally growing HeLa cells, Y79 cells, and APL cells presented 
a comparable distribution of G1, S, and G2/M cells, the level 
ofpl6 expression ismuch higher in HeLa cells than in the other 
two lines. From these data we can conclude that there is no 
correlation between p16 protein expression and S-phase con- 
tent of these logarithmically growing cells. We also want to 
speculate that the capacity of papilloma virus to increase p16 
expression in cycling cells is distinct from the capacity of this 
virus to induce cell entry into S-phase and thereby fast cell 
cycling of growing cells. 
We separated phytohemagglutinin-stimulated human lym- 
phocytes according to their phase of the cell cycle by centrifugal 
elutriation. These cells are neither immortalized nor trans- 
formed, and therefore provide an optimal system to study p16 
regulation throughout the normal eukaryotic ell cycle. West- 
ern blot analysis revealed that pl 6 protein expression isnot cell 
cycle regulated in these cells (Fig. 1). The maximal fluctuation 
of p16 protein amount between the different fractions was not 
more than 1.3-fold. Loss of retinoblastoma protein did not 
influence the course of cell cycle regulation of this cyclin-de- 
pendent kinase inhibitor, pRb-negative Y79 cells did not ex- 
hibit any fluctuation of p16 protein during their ongoing cell 
cycle (Fig. 1). To ask whether any other form of transforma- 
tion, which does not influence regulations involving pRb, DNA 
tumor viruses, and/or the transcription factor E2F, leads to 
alterations of p16 regulation, we studied acute promyelocytic 
leukemia cells (APL). Not surprisingly, those cells did not ex- 
hibit cell cycle-dependent fluctuations of p 16 protein expression 
either (Fig. 2). Studying logarithmically growing cells, we dem- 
onstrated that papilloma virus-transformed HeLa cells exhibit 
highly increased p16 protein levels compared to normal lym- 
phocytes, pRb-negative cells and APL cells. Accordingly, the 
question arose whether p16 protein expression is upregulated 
in all phases of the cell cycle of HeLa cells, or if its expression 
is deregulated in these cells. Centrifugal elutriation experiments 
revealed that p16 protein is not cell cycle regulated in HeLa 
cells (Fig. 2). One must conclude that this CDK-inhibitor is 
higher expressed in all cell cycle phases (G1, S, G2) of HeLa 
cells compared to normal cells, such as phytohemagglutinin- 
stimulated lymphocytes. Absolute quantitative comparison of 
p16 protein levels in the different phases of the cell cycle of 
HeLa cells and PHA-lymph cells demonstrated that HeLa cells 
indeed express much more p16 protein in all phases of the cell 
cycle (data not shown). 
3.3. p16 mRNA expression throughout the ongoing cell cycle 
We further asked at which level the cell cycle independent 
regulation of p16 protein is determined. It might be that p16 
mRNA is expressed at a very defined time point during the 
eukaryotic ell cycle, but p16 protein is so stable that mRNA 
fluctuations are not reflected in protein regulation. However, 
Northern blot analyses after centrifugal elutriation demon- 
strated that p16 mRNA is constitutively expressed throughout 
the cell cycle (Fig. 3). 
Furthermore, quantitative comparison revealed that p16 
mRNA is constantly much higher expressed in HeLa cells than 
in normal lymphocytes. These data allow to conclude that 
papilloma virus transformation leads to an upregulation of pl 6 
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tion of the expression of this inhibitor [12,15-17]. We examined 
the regulation of this cyclin-dependent kinase inhibitor during 
the ongoing cell cycle after centrifugal elutriation. Neither pl 6 
mRNA nor its protein expression are regulated uring the cell 
cycle of normal phytohemagglutinin-stimulated ymphocytes, 
retinoblastoma protein-negative c lls, papilloma virus-trans- 
formed HeLa cells, and acute promyelocytic leukemia cells. 
However, the fact that we did not observe cell cycle specific 
regulation of p16 does not exclude the possibility that E2F 
plays a role in the basal expression or the growth regulation of 
this CDK-inhibitor. There are examples for both E2F-depend- 
ent genes which are S-phase regulated uring the ongoing cell 
cycle and for E2F-regulated genes which are not. The DNA 
precursor pathway enzyme thymidine kinase has been shown 
to be regulated via E2F [21]. Furthermore, TK expression is 
known to be low in Go and to dramatically increase before the 
onset of S-phase after restimulation (reviewed in [23]). It has 
Fig. 2. p16 protein expression throughout the cell cycle of acute promy- 
elocytic leukemia cells (APL) and of papilloma virus transformed HeLa 
cells. Ceils were separated according to their phases of the cell cycle by 
centrifugal elutriation. Cytofluorometric analyses of the DNA distribu- 
tions of the separated fractions are presented on top of the figure. 
Western blot analysis and its quantification are presented in the middle 
and the lower pannel (compare Fig. 1). 
protein expression determined by an induction of p16 mRNA 
expression in all phases of the cell cycle. 
As described above it has been speculated that p16 expres- 
sion could be regulated via the transcription factor E2F [12,15- 
17]. To ensure that fluctuations of E2F-dependent transcription 
throughout the cell cycle can be detected in our normal ympho- 
cytes, we rehybridized the Northern blot shown in Fig. 3 with 
a thymidine kinase (TK) cDNA-probe. Expression of TK 
mRNA has been shown to be regulated via E2F [21] and to 
increase at the G1/S boundary and decrease during G2 of the 
normal ongoing cell cycle [22]. We demonstrated that TK 
mRNA is cell cycle-regulated in the same cells in which p16 
expression is cell cycle-independent (Fig. 4). The main antago- 
nist of p 16 is cyclin D l, because it activates CDK4 and CDK6. 
Cyclin D1 mRNA expression is high in early G1 and decreases 
during S-phase of the cell cycle (Fig. 4). 
4. Discuss ion 
It has earlier been demonstrated that p16, the inhibitor of 
cyclin dependent kinase 4 and 6, is overexpressed in retinoblas- 
toma protein-negative c lls as well as in DNA tumor virus- 
transformed cells [6,12,13,17]. This observation and the fact 
that p16 protein expression increases when growth-arrested 
ceils are restimulated [12] led to the speculation about the pos- 
sible involvement of the transcription factor E2F in the regula- 
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Fig. 3. Regulation of p16 mRNA expression throughout the ongoing 
cell cycle. Logarithmically growing phytohemagglutinin-stimulated 
lymphocytes (PHA-lymph) and HeLa cells were separated into frac- 
tions of different cell cycle phases by centrifugal elutriation. The frac- 
tions were cytofluorometrically analysed for DNA distribution (upper 
panel), mRNA of each fraction was blotted to nylon and sequentially 
hybridized with p 16 cDNA (pl 6) and cDN A of glyceraldehyde-3-phos- 
phate dehydrogenase (GAPDH). The Northern blot signals were den- 
sitometrically quantified and p16 mRNA expression was related to 
GAPDH expression (the highest value was set to 100%; lower panel). 
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Fig. 4. mRNA expression of p16, thymidine kinase and cyclin D1 
throughout the cell cycle of normal ymphocytes. The expression of 
these genes has been normalized to the levels of GAPDH mRNA 
expression. The highest value within each analysed gene has been set 
to 100% (values between different genes are not comparable). 
recently been demonstrated that TK mRNA as well as protein 
expression is S-phase regulated throughout the normal ongoing 
cell cycle [22,24]. On the other hand, the oncogene c-myc has 
also been shown to be regulated via the transcription factor 
E2F [25]. Although c-myc expression ishighly upregulated dur- 
ing restimulation from Go to logarithmic growth, it is conti- 
nously expressed in proliferating cells in a cell cycle-independ- 
ent manner [26]. 
The interplay of cyclins, cyclin-dependent kinases, the inhib- 
itors of these kinases, and pRb enables the cell cycle clock to 
control its own forward progress. One described circuit, which 
is responsible for the regulation of the transition of cycling cells 
over the restriction point in mid to late G1, involves the D type 
cyclins, CDK 4 and CDK6, and the specific inhibitor of these 
two kinases, pl6. CDK4 as well as CDK6 phosphorylate pRb 
and thereby activate the transcription factor E2F, to promote 
S-phase-specific gene expression (reviewed in [5,14,15]). The 
expression of these cyclin-dependent kinases is constant 
throughout the cell cycle; their regulation occurs at other levels. 
Binding of D-type cyclins to these CDKs as well as phosphoryl- 
ation of these CDKs by the cyclin-dependent kinase activating 
kinase (CAK) induce their activites. Binding of pl6 to CDK4 
and/or CDK6 inhibits their association with D-type cyclins and 
thereby inactivates these kinases (reviewed in [5] and [27]). The 
question arising is, how are the activities of CDK4 and CDK6 
restricted to a cell cycle period from mid to late G 1 ? The earlier 
observation that pl6 is growth-regulated induced speculations 
about the following model of CDK4/CDK6 regulation during 
the ongoing cell cycle [12,15-17]: Cyclin D is transcriptionally 
upregulated in early G1 and subsequently activates CDK4 and 
CDK6 to phosphorylate pRb. Phosphorylated Retinoblastoma 
protein releases a transcription factor that induces pl6 expres- 
sion. pl6 causes dissociation of the cyclin D/CDK complexes 
by binding to the kinases. Thereafter, cyclin D, not longer 
protected by association with CDK4/CDK6, is degraded. This 
model suggested that CDK4 and CDK6 activities are switched 
on by the transcriptional upregulation of D-type cyclins in G1, 
and are switched off by the transcriptional upregulation of the 
cyclin-dependent kinase inhibitor pl6. In accord with this 
model, one would expect to detect a sharp increase of pl6 
expression i  late G1. The data we present in this report do not 
support this model, since we did not observe any cell cycle- 
dependent regulation of pl6 expression throughout the ongo- 
ing cell cycle. 
When pl6 is not regulated uring the cell cycle, how are the 
activites of CDK4 and CDK6 restricted to GI? We favour a 
model in which the main cell cycle regulators of these kinase 
activities are the D-type cyclins (compare Fig. 4). Analysing 
expression during the ongoing cell cycle after centrifugal elutri- 
ation, we observed high levels of cyclin D1 in early G1 and a 
very sharp decrease of its expression at the G1/S boundary. Our 
results are in agreement with earlier data on cyclin D1 expres- 
sion during restimulation of arrested normal diploid fibro- 
blasts: The level of cyclin D1 was low in quiescent cells, and in 
early G1 the protein was synthesized rapidly and accumulated 
steadily. As cells entered S-phase cyclin D1 disappeared from 
the nucleus and the total abundance of the protein decreased 
[28]. In the same cells, in which we observed the Gl-phase 
specific cyclin D1 expression, pl6 was constantly expressed 
over the cell cycle, whereas the E2F-dependent transcription of 
thymidine kinase is highly increased at the G1 to S-phase tran- 
sition. Accordingly, we suggest hat as long as high levels of 
D-type cyclins are expressed in the cell, their antagonist pl6 
cannot bind to CDK4 and/or CDK6 and thereby inactivate 
them. During that time E2F-dependent transcription is in- 
duced, as detectable by TK mRNA expression. After the G1/S 
boundary mRNA transcription of cyclin D is switched off and 
pl6 protein can inhibit the kinase activities. This suggestion is
in perfect agreement with our earlier observation that E2F- 
dependent transcription of thymidine kinase and dihydrofolate 
reductase is induced during a short and very distinct ime pe- 
riod, ranging from late G1 to mid S. During S-phase this E2F- 
dependent transcription already decreases again [24]. However, 
although our proposed model can explain how the interactions 
between pl6, D-type cyclins, and CDK4/CDK6 could be cell 
cycle-regulated, the G1/S-regulation of E2F-dependent tran- 
scription is more complicated, since another complex formed 
between CDK2 and cyclin E also phosphorylates pRb in late 
G1 and thereby activates E2F [5,15,27]. 
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